OpenEvidence Raises $75 Million in Series A
OpenEvidence, a Cambridge, MA-based AI-powered medical information platform, has secured $75 million in funding at a $1 billion valuation.
OpenEvidence, a Cambridge, MA-based AI-powered medical information platform, has secured $75 million in funding at a $1 billion valuation.
Investor
The funding round was from Sequoia Capital, bringing OpenEvidence's total capital raised to over $100 million.
Sequoia Capital, headquartered in Menlo Park, California, is a venture capital firm specializing in seed-stage, early-stage, and growth-stage investments across technology sectors. It helps founders build legendary companies from inception to IPO and beyond.
OpenEvidence Use of Funds
The company will use the funds to scale operations, train next-gen medical LLMs, recruit top talent, and expand its medical knowledge library through strategic partnerships.
About OpenEvidence
Founded in 2021 by Daniel Nadler, OpenEvidence is on a mission to organize and expand the world's collective medical knowledge, offering an AI copilot for doctors that assists them in making critical decisions at the point of care. The platform offering insights on treatments, drug safety, disease causes, and more—tailored to specific patient factors. The company has signed a multi-year content agreement with the NEJM Group, publisher of the New England Journal of Medicine (NEJM). OpenEvidence is free for verified doctors in the United States but is a professional tool available only to healthcare providers.
Funding Details
Company: OpenEvidence
Raised: $75.0M
Round: Series A
Funding Date: February 2025
Investor: Sequoia Capital
Company Website: https://www.openevidence.com/
Software Category: Clinical Decision Support
